The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
As EDs across the country strive to meet sepsis benchmark metrics, many have implemented a variety of screening tools. With the publication of Sepsis-3,...
Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic...
Mechanically ventilating the patient with a severe asthma exacerbation is fraught with peril. Incorrect settings for tidal volume, respiratory rate, pressure triggers, or inspiratory...
